Trial · NCT05410418
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
NCT05410418, Phase 2, Active not recruiting, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma. Trials, record NCT05410418. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05410418
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
- NCT number
- NCT05410418
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Lymphoma, Follicular, Follicular Lymphoma
- Interventions
- Mosunetuzumab, Polatuzumab vedotin
- First posted
- 2022-06-08
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Complete Response (CR) as Best Response | Through completion of treatment (estimated to be 1 year) | CR determined by response to treatment by PET-CT at end of treatment per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Number of Participants With Complete Response (CR) | After Cycle 8 (each cycle is 21 days; estimated to be 6 months) | CR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Number of Participants With Partial Response (PR) | After Cycle 8 (each cycle is 21 days; estimated to be 6 months) | PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Number of Participants With Partial Response (PR) as Best Response | Through completion of treatment (estimated to be 1 year) | PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR) | After Cycle 8 (each cycle is 21 days; estimated to be 6 months) | CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Overall Response Rate (ORR) as Measured by Number of Participants With Complete Response (CR) and Partial Response (PR) | Through completion of treatment (estimated to be 1 year) | CR and PR determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Number of Participants With Stable Disease (SD) | After Cycle 8 (each cycle is 21 days; estimated to be 6 months) | SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Number of Participants With Stable Disease (SD) as Best Response | Through completion of treatment (estimated to be 1 year) | SD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Number of Participants With Progressive Disease (PD) | After Cycle 8 (each cycle is 21 days; estimated to be 6 months) | PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
| Secondary | Number of Participants With Progressive Disease (PD) as Best Response | Through completion of treatment (estimated to be 1 year) | PD determined by response to treatment by PET-CT after Cycle 8 per Deauville 5-point scale (Lugano 2014 criteria). The Deauville scale is scored from 1 to 5, with 1 indicating no uptake on PET-CT and 5 indicating markedly increased uptake on PET-CT. |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05410418
GET https://conductscience.org/api/trials/v1/NCT05410418/registered?page=2